The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT): The largest hypertension study ever undertaken: Baseline characteristics

被引：0

作者：

Grimm, RH

Davis, BR

Ford, C

Alderman, MH

Black, HR

Cushman, WC

Dequattro, V

Papademetriou, V

机构：

[1] SHAPIRO CTR EVIDENCE BASED MED,MINNEAPOLIS,MN

[2] COORDINATING CTR CLIN TRIALS,HOUSTON,TX

[3] ALBERT EINSTEIN COLL MED,BRONX,NY 10467

[4] RUSH MED COLL,CHICAGO,IL 60612

[5] UNIV TENNESSEE,MEMPHIS,TN

[6] UNIV SO CALIF,LOS ANGELES,CA

[7] MINNEAPOLIS MED RES FDN INC,WASHINGTON,DC

来源：

CIRCULATION | 1997年 / 96卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1542 / 1542

页数：1

共 50 条

[21] Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Probstfield, J. L.
Cushman, W. C.
Davis, B. R.
Pressel, S.
Cutler, J. A.
Einhorn, P.
Ford, C.
Oparil, S.
Whelton, P.
Wright, J. T.
EUROPEAN HEART JOURNAL, 2010, 31 : 321 - 321
[22] Predictors of Incident Conduction System Disease in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Dewland, Thomas A.
Soliman, Elsayed Z.
Davis, Barry R.
Magnani, Jared W.
Yamal, Jose-Miguel
Piller, Linda B.
Haywood, L. Julian
Marcus, Gregory M.
CIRCULATION, 2014, 130
[23] The antihypertensive and lipid-lowering treatment to prevent heart attack trial
Flack, JM
Nasser, SA
CURRENT HYPERTENSION REPORTS, 2003, 5 (03) : 189 - 191
[24] Blood Pressure Control by Drug Group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Cushman, William C.
Ford, Charles E.
Einhorn, Paula T.
Wright, Jackson T., Jr.
Preston, Richard A.
Davis, Barry R.
Basile, Jan N.
Whelton, Paul K.
Weiss, Robert J.
Bastien, Arnaud
Courtney, Donald L.
Hamilton, Bruce P.
Kirchner, Kent
Louis, Gail T.
Retta, Tamrat M.
Vidt, Donald G.
JOURNAL OF CLINICAL HYPERTENSION, 2008, 10 (10): : 751 - 760
[25] TOWARD IDENTIFYING PERSONALIZED PROGNOSIS IN HYPERTENSION: VARIATION IN EARLY RESPONSES IN THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)
Dhruva, Sanket Shishir
Huang, Chenxi
Spatz, Erica
Coppi, Andreas
Warner, Frederick
Li, Shu-Xia
Lin, Haiqun
Xu, Xiao
Furberg, Curt
Davis, Barry
Pressel, Sara
Coifman, Ronald
Krumholz, Harlan
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1762 - 1762
[26] Clinical implications of recent findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and other studies of hypertension
Furberg, CD
Psaty, BM
Pahor, M
Alderman, MH
ANNALS OF INTERNAL MEDICINE, 2001, 135 (12) : 1074 - 1078
[27] THE EFFECT OF RENAL FUNCTION ON INCIDENCE OF CONGESTIVE HEART FAILURE: THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) STUDY
Kholghi, Maedeh Khayyat
Oparil, Suzanne
Davis, Barry
Tereshchenko, Larisa G.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 752 - 752
[28] Follow-up specialists in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - Contribution to study closeout
Pressel, S
Davis, B
Blanton, J
CONTROLLED CLINICAL TRIALS, 2003, 24 : 116S - 117S
[29] Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone
Piller, LB
Davis, BR
Cutler, JA
Cushman, WC
Wright, JT
Williamson, JD
Leenen, FH
Einhorn, PT
Randall, OS
Golden, JS
Haywood, LJ
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2002, 3 (1):
[30] Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone
Linda B Piller
Barry R Davis
Jeffrey A Cutler
William C Cushman
Jackson T Wright
Jeff D Williamson
Frans HH Leenen
Paula T Einhorn
Otelio S Randall
John S Golden
L Julian Haywood
Current Controlled Trials in Cardiovascular Medicine, 2002, 3

← 1 2 3 4 5 →